Startup Professionals Musings
NOVEMBER 4, 2022
Being the leader doesn’t mean more equity, nor does it mean the leader will necessarily be CEO. Young high-tech startups are at constant risk of forgetting that they actually need to sell the wonderful technology they invented. It just means that the cofounders trust one of their own and are willing to follow.
Startup Professionals Musings
FEBRUARY 9, 2020
Being the leader doesn’t mean more equity, nor does it mean the leader will necessarily be CEO. Young high-tech startups are at constant risk of forgetting that they actually need to sell the wonderful technology they invented. It just means that the cofounders trust one of their own and are willing to follow.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Startup Professionals Musings
SEPTEMBER 13, 2015
Being the leader doesn’t mean more equity, nor does it mean the leader will necessarily be CEO. Young high-tech startups are at constant risk of forgetting that they actually need to sell the wonderful technology they invented. It just means that the cofounders trust one of their own and are willing to follow.
Startup Professionals Musings
FEBRUARY 18, 2018
Being the leader doesn’t mean more equity, nor does it mean the leader will necessarily be CEO. Young high-tech startups are at constant risk of forgetting that they actually need to sell the wonderful technology they invented. It just means that the cofounders trust one of their own and are willing to follow.
Startup Professionals Musings
JUNE 11, 2014
Being the leader doesn’t mean more equity, nor does it mean the leader will necessarily be CEO. Young high-tech startups are at constant risk of forgetting that they actually need to sell the wonderful technology they invented. It just means that the cofounders trust one of their own and are willing to follow.
socalTECH
JULY 27, 2020
We caught up with Nick--who is a veteran of the area's high tech industry, most recently serving as CEO of Velocify--to get the latest on MomentFeed, which provides services to multi-brand, location businesses. Nick Hedges: We have a pretty competitive space, so there are a number of players. Remind us who is backing MomentFeed?
Xconomy
JUNE 3, 2016
The only remaining daptomycin patent will expire in June, clearing the way for generic competition years earlier than expected. Contravir will pay $17 million in cash and 10 percent of its equity to Ciclofilin shareholders, but only if the company’s lead drug, CPI-431-32, hits certain milestones.
Expert insights. Personalized for you.
123 
Let's personalize your content